Compare GAIA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GAIA | ACET |
|---|---|---|
| Founded | 1988 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.9M | 77.3M |
| IPO Year | 1999 | 2017 |
| Metric | GAIA | ACET |
|---|---|---|
| Price | $3.03 | $7.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.50 | ★ $48.33 |
| AVG Volume (30 Days) | 56.7K | ★ 134.8K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.18 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,500,000.00 | N/A |
| Revenue This Year | $13.07 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.50 | N/A |
| 52 Week Low | $2.45 | $0.46 |
| 52 Week High | $6.39 | $9.05 |
| Indicator | GAIA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 51.30 |
| Support Level | $2.98 | $6.28 |
| Resistance Level | $3.46 | $8.46 |
| Average True Range (ATR) | 0.12 | 0.48 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 75.00 | 55.11 |
Gaia Inc is a video streaming service and community that provides curated conscious media in primary channels; Seeking Truth provides new and enlightening perspectives for today's changing world; Transformation provides a wealth of content in the niche areas of spiritual growth, personal development, and expanded consciousness; Alternative Healing channel features content focused on food and nutrition, holistic healing, alternative and integrative medicines, and longevity, and Yoga. The company operates in a single reporting segment. Its revenues is derived from subscription fees for services related to streaming content to the members. Geographically, it derives a majority of its revenue from the United States and also has an International presence.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).